RS55466B1 - Supstituisani 6-amino-nikotinamidi koji imaju grupu koja sadrži oh kao modulatori kcnq2/3 - Google Patents
Supstituisani 6-amino-nikotinamidi koji imaju grupu koja sadrži oh kao modulatori kcnq2/3Info
- Publication number
- RS55466B1 RS55466B1 RS20161120A RSP20161120A RS55466B1 RS 55466 B1 RS55466 B1 RS 55466B1 RS 20161120 A RS20161120 A RS 20161120A RS P20161120 A RSP20161120 A RS P20161120A RS 55466 B1 RS55466 B1 RS 55466B1
- Authority
- RS
- Serbia
- Prior art keywords
- aliphatic residue
- residue
- unsubstituted
- polysubstituted
- mono
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12002709 | 2012-04-18 | ||
| PCT/EP2013/001134 WO2013156154A1 (en) | 2012-04-18 | 2013-04-17 | Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators |
| EP13719386.8A EP2888233B1 (en) | 2012-04-18 | 2013-04-17 | Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS55466B1 true RS55466B1 (sr) | 2017-04-28 |
Family
ID=48227140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20161120A RS55466B1 (sr) | 2012-04-18 | 2013-04-17 | Supstituisani 6-amino-nikotinamidi koji imaju grupu koja sadrži oh kao modulatori kcnq2/3 |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP2888233B1 (enExample) |
| JP (1) | JP6033403B2 (enExample) |
| CN (1) | CN104428287A (enExample) |
| AR (1) | AR090739A1 (enExample) |
| AU (1) | AU2013248637A1 (enExample) |
| BR (1) | BR112014025840A2 (enExample) |
| CA (1) | CA2870573A1 (enExample) |
| CY (1) | CY1118255T1 (enExample) |
| DK (1) | DK2888233T3 (enExample) |
| EA (1) | EA201401142A1 (enExample) |
| ES (1) | ES2605947T3 (enExample) |
| HK (1) | HK1210173A1 (enExample) |
| HR (1) | HRP20161424T1 (enExample) |
| HU (1) | HUE030859T2 (enExample) |
| IL (1) | IL235030A0 (enExample) |
| LT (1) | LT2888233T (enExample) |
| MX (1) | MX2014012494A (enExample) |
| PT (1) | PT2888233T (enExample) |
| RS (1) | RS55466B1 (enExample) |
| SI (1) | SI2888233T1 (enExample) |
| WO (1) | WO2013156154A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018071654A2 (pt) * | 2016-04-22 | 2019-02-19 | Ono Pharmaceutical Co., Ltd. | polimorfismo de cristal do ativador de canais kcnq2-5 |
| JP7262468B2 (ja) * | 2017-12-29 | 2023-04-21 | スリーエム イノベイティブ プロパティズ カンパニー | 熱硬化性２剤型加工用接着剤組成物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2230392A1 (de) | 1972-06-22 | 1974-01-31 | Cassella Farbwerke Mainkur Ag | Substituierte pyridinverbindungen und verfahren zu ihrer herstellung |
| DE2513949A1 (de) | 1975-03-29 | 1976-10-07 | Bayer Ag | Azofarbstoffe |
| MXPA03007397A (es) | 2001-02-20 | 2003-12-04 | Bristol Myers Squibb Co | Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas. |
| EP1361879A1 (en) * | 2001-02-20 | 2003-11-19 | Bristol-Myers Squibb Company | 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators |
| EP2086935A1 (de) * | 2006-10-16 | 2009-08-12 | Grünenthal GmbH | Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren |
| DE102006049452A1 (de) | 2006-10-17 | 2008-05-08 | Grünenthal GmbH | Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln |
| DK2350093T3 (da) | 2008-10-24 | 2012-11-12 | Gruenenthal Gmbh | Substituerede 4,5,6,7-tetrahydrothienopyridiner som KCNQ2/3-modulatorer til behandling af smerte, epilepsi og urininkontinens. |
| TWI475020B (zh) * | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
| US8552200B2 (en) * | 2010-10-20 | 2013-10-08 | Gruenenthal Gmbh | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators |
-
2013
- 2013-04-17 BR BR112014025840A patent/BR112014025840A2/pt not_active IP Right Cessation
- 2013-04-17 PT PT137193868T patent/PT2888233T/pt unknown
- 2013-04-17 AU AU2013248637A patent/AU2013248637A1/en not_active Abandoned
- 2013-04-17 HR HRP20161424TT patent/HRP20161424T1/hr unknown
- 2013-04-17 CA CA2870573A patent/CA2870573A1/en not_active Abandoned
- 2013-04-17 CN CN201380019282.3A patent/CN104428287A/zh active Pending
- 2013-04-17 LT LTEP13719386.8T patent/LT2888233T/lt unknown
- 2013-04-17 HK HK15111080.1A patent/HK1210173A1/xx unknown
- 2013-04-17 WO PCT/EP2013/001134 patent/WO2013156154A1/en not_active Ceased
- 2013-04-17 HU HUE13719386A patent/HUE030859T2/en unknown
- 2013-04-17 MX MX2014012494A patent/MX2014012494A/es unknown
- 2013-04-17 EP EP13719386.8A patent/EP2888233B1/en not_active Not-in-force
- 2013-04-17 EA EA201401142A patent/EA201401142A1/ru unknown
- 2013-04-17 SI SI201330394A patent/SI2888233T1/sl unknown
- 2013-04-17 ES ES13719386.8T patent/ES2605947T3/es active Active
- 2013-04-17 DK DK13719386.8T patent/DK2888233T3/en active
- 2013-04-17 RS RS20161120A patent/RS55466B1/sr unknown
- 2013-04-17 JP JP2015506121A patent/JP6033403B2/ja not_active Expired - Fee Related
- 2013-04-18 AR ARP130101283A patent/AR090739A1/es unknown
-
2014
- 2014-10-07 IL IL235030A patent/IL235030A0/en unknown
-
2016
- 2016-11-24 CY CY20161101222T patent/CY1118255T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6033403B2 (ja) | 2016-11-30 |
| SI2888233T1 (sl) | 2016-12-30 |
| PT2888233T (pt) | 2017-01-04 |
| EP2888233A1 (en) | 2015-07-01 |
| EP2888233B1 (en) | 2016-09-28 |
| HRP20161424T1 (hr) | 2016-12-16 |
| CY1118255T1 (el) | 2017-06-28 |
| WO2013156154A1 (en) | 2013-10-24 |
| ES2605947T3 (es) | 2017-03-17 |
| MX2014012494A (es) | 2015-01-15 |
| AU2013248637A1 (en) | 2014-12-04 |
| EA201401142A1 (ru) | 2015-03-31 |
| AR090739A1 (es) | 2014-12-03 |
| CA2870573A1 (en) | 2013-10-24 |
| JP2015514728A (ja) | 2015-05-21 |
| DK2888233T3 (en) | 2017-01-09 |
| HUE030859T2 (en) | 2017-06-28 |
| LT2888233T (lt) | 2017-01-10 |
| IL235030A0 (en) | 2014-12-31 |
| CN104428287A (zh) | 2015-03-18 |
| HK1210173A1 (en) | 2016-04-15 |
| BR112014025840A2 (pt) | 2017-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD20150019A2 (ro) | Alcoxipirazoli în calitate de activatori ai guanilat ciclazei solubile | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| PE20120307A1 (es) | Derivados de indazol como antagonistas del receptor ccr4 | |
| RU2013118209A (ru) | Фармацевтическая композиция | |
| PE20140630A1 (es) | Derivados de acido 3-fenilpropionico ramificados y su uso | |
| HRP20171453T1 (hr) | Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita | |
| EP3725801A3 (en) | Amino diacids containing peptide modifiers | |
| HRP20210526T1 (hr) | Oksisteroli i postupci za njihovu uporabu | |
| PE20140836A1 (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide | |
| NZ594928A (en) | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | |
| PH12018501849A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| WO2012007877A3 (en) | N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels | |
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| NZ709648A (en) | Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-methyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl)benzamide and its mono hydrochloride salt | |
| MX383551B (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida | |
| TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| FI3572405T3 (fi) | Benzoimidatsol-1,2-yyli amidit kv7 kanavan aktivaattoreina | |
| NZ701933A (en) | Phenoxyethyl piperidine compounds | |
| NZ604035A (en) | Glycine transporter-1 inhibitors, methods of making them, and uses thereof | |
| MY174254A (en) | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | |
| PE20161369A1 (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona sustituidos con tetrazolona | |
| PL417980A1 (pl) | Nowe fosfotriazolowe analogi kapu końca 5' mRNA, kompozycja je zawierająca, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA, białka i peptydu | |
| MX2012013610A (es) | Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina. | |
| HRP20150526T1 (hr) | Supstituirani 2-oksi-kinolin-3-karboksamidi kao modulatori kcnq2/3 | |
| GB201018519D0 (en) | Novel treatment of multiple sclerosis (MS) |